Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Buprenorphine
Drug ID BADD_D00310
Description Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction.[F4715,F4718] Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,F4715,F4718] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet.
Indications and Usage For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
Marketing Status Prescription; Discontinued
ATC Code N02AE01; N07BC01
DrugBank ID DB00921
KEGG ID D07132
MeSH ID D002047
PubChem ID 644073
TTD Drug ID D06AWE
NDC Product Code 51927-0062; 12578-607; 65724-0050; 0093-3659; 71335-0353; 42858-586; 60687-492; 62756-460; 59011-750; 65267-203; 67509-003; 12496-0100; 60687-481; 42858-353; 69238-1203; 42858-501; 59011-758; 62756-459; 71335-1154; 12496-0300; 69238-1505; 38779-3255; 59011-751; 68071-2592; 59011-757; 50090-5805; 73548-1039; 0093-3657; 0792-0631; 59011-752; 71335-0950; 69238-1202; 69238-1204; 0228-3153; 42858-502; 49812-0239; 0093-3239; 70518-1625; 42858-750; 0093-3658; 42858-493; 42858-839; 71795-2200; 0093-3656; 10920-593; 0228-3156; 12707-036; 47848-030; 69238-1205
Synonyms Buprenorphine | Buprenex | Prefin | Subutex | Buprex | Temgesic | Temgésic | 6029-M | 6029 M | 6029M | RX-6029-M | RX 6029 M | RX6029M | Buprenorphine Hydrochloride | Hydrochloride, Buprenorphine
Chemical Information
Molecular Formula C29H41NO4
CAS Registry Number 52485-79-7
SMILES CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatitis C09.01.09.005; 11.05.06.0040.001859%Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hiccups22.02.04.002; 07.01.06.009--
Hyperhidrosis23.02.03.004; 08.01.03.0280.104078%
Hypersensitivity10.01.03.0030.014868%
Hypersomnia19.02.05.001; 17.15.01.0010.007434%
Hypertension24.08.02.001--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokinesia17.01.02.0090.001859%Not Available
Hypopnoea22.02.01.0210.002788%Not Available
Hypotension24.06.03.002--
Hypoventilation22.02.01.007--Not Available
Ileus07.13.01.001--
Incoherent17.02.08.002; 19.10.03.0060.002788%Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Influenza like illness08.01.03.0100.017656%
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.0020.046464%
Irritability19.04.02.013; 08.01.03.0110.013939%
Joint stiffness15.01.02.0030.001859%Not Available
Joint swelling15.01.02.004--Not Available
Lacrimation increased06.08.02.0040.005576%
Laryngeal pain22.02.05.036--
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.016727%
Libido decreased21.03.02.005; 19.08.03.0010.001859%
Limb malformation15.11.07.006; 03.11.07.0060.003717%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.002788%Not Available
Local swelling08.01.03.0130.002788%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages